Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators. Earl HM, et al. Lancet Oncol. 2017 Jun;18(6):755-769. doi: 10.1016/S1470-2045(17)30319-4. Epub 2017 May 4. Lancet Oncol. 2017. PMID: 28479233 Free article. Clinical Trial.
Etoposide protein binding in cancer patients.
Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ. Liu B, et al. Among authors: earl hm. Cancer Chemother Pharmacol. 1995;36(6):506-12. doi: 10.1007/BF00685801. Cancer Chemother Pharmacol. 1995. PMID: 7554043
Chemotherapy for ovarian cancer--a consensus statement on standard practice.
Adams M, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM. Adams M, et al. Among authors: earl hm. Br J Cancer. 1998 Dec;78(11):1404-6. doi: 10.1038/bjc.1998.699. Br J Cancer. 1998. PMID: 9836470 Free PMC article. No abstract available.
Whither high-dose chemotherapy in breast cancer?
Mayer A, Earl H. Mayer A, et al. Breast Cancer Res. 2001;3(1):8-10. doi: 10.1186/bcr262. Epub 2000 Nov 8. Breast Cancer Res. 2001. PMID: 11250740 Free PMC article. Review.
A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.
Johnston SR, Gumbrell LA, Evans TR, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A, Canney P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarman M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC; Cancer Research UK Phase I/II Committee. Johnston SR, et al. Among authors: earl hm. Cancer Chemother Pharmacol. 2004 Apr;53(4):341-8. doi: 10.1007/s00280-003-0733-6. Epub 2004 Jan 13. Cancer Chemother Pharmacol. 2004. PMID: 14722733 Clinical Trial.
140 results